A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy
Condition: Carcinoma, Non-small Cell Lung Interventions: Biological: nivolumab; Biological: ipilimumab; Drug: cabozantinib; Drug: docetaxel; Biological: ramucirumab; Drug: lucitanib Sponsor: Bristol-Myers Squibb Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Research | Study | Taxotere | Yervoy